Zevra Therapeutics Insider Gains 66,666 Shares in Routine RSU Conversion

Rhea-AI Filing Summary

Zevra Therapeutics, Inc. (ZVRA) – Form 4 filing dated 06/24/2025

The filing discloses an equity transaction by insider Rahsaan W. Thompson, who serves as Chief Legal & Compliance Officer and Secretary. On 06/21/2025, Thompson acquired 66,666 shares of common stock through the settlement of previously granted restricted stock units (RSUs). The transaction is coded “M,” indicating a conversion of a derivative security rather than an open-market purchase or sale.

Table II shows the RSU award underlying the transaction. The original grant totals 133,334 RSUs. According to the vesting schedule, one-third (66,666 units) vested and converted to common stock on 06/21/2025; the remaining two tranches will vest in equal annual installments, subject to continued service. Following the settlement, Thompson directly holds 66,666 shares of common stock and retains 133,334 unvested RSUs that may convert into an equal number of shares over the next two years.

No price is listed for the RSUs because the grant is equity-settled at no cash cost to the insider. There is no indication of open-market buying or selling, no mention of a 10b5-1 trading plan check-box selection, and no other classes of securities were involved. The filing is routine and does not provide information on company operations, earnings, or strategic initiatives.

Insights

Financial Analyst

TL;DR: Routine RSU vesting; insider gains 66,666 shares, no cash outlay, minimal direct market impact.

The Form 4 reflects standard compensation-related equity vesting for Chief Legal & Compliance Officer Rahsaan Thompson. Code “M” confirms a non-open-market conversion of RSUs, meaning no supply-demand pressure on ZVRA shares. Post-transaction holdings are modest relative to Zevra’s total shares outstanding, so signaling value is limited. No sales occurred, and the insider still holds 133,334 unvested RSUs that align incentives with long-term performance. Because it neither adds buying pressure nor indicates disposition, the filing is neutral from a valuation standpoint.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Rahsaan

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Legal & Compliance		Secretary

3. Date of Earliest Transaction (Month/Day/Year)
06/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/21/2025		M		66,666	A	(1)	66,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	06/21/2025		M			66,666	(2)	(2)	Common Stock	66,666	$0	133,334	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. The first tranche of the restricted stock units vested and settled on June 21, 2025, and the remaining two tranches of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Rahsaan W. Thompson	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Zevra Therapeutics (ZVRA) shares did Rahsaan Thompson acquire on 06/21/2025?

The insider acquired 66,666 shares of common stock through RSU settlement.

What is the total unvested RSU balance remaining for the insider after this Form 4?

Thompson retains 133,334 unvested restricted stock units that will vest in two equal annual tranches.

Did the insider buy or sell ZVRA shares on the open market?

No. The filing lists transaction code “M”, indicating an RSU conversion, not an open-market trade.

Is the transaction part of a Rule 10b5-1 trading plan?

The check-box for a Rule 10b5-1 plan is not marked; therefore, the filing does not indicate such a plan.

What role does Rahsaan Thompson hold at Zevra Therapeutics?

He is the company’s Chief Legal & Compliance Officer and Secretary.